From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Sat, 11 Apr 2020 18:10:39 +0000
To:
Subject: FW: Wpost: Gilead’s experimental drug remdesivir shows hopeful’ signs in

small group of coronavirus patients https://wapo.st/2wzjsy2

Geeez....

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: C

FAX: (3 1 109

 

The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [OY >

Sent: Friday, April 10, 2020 5:30 PM
Subject: Wpost: Gilead’s experimental drug remdesivir shows ‘hopeful’ signs in small group of
coronavirus patients https://wapo.st/2wzjsy2

Business
Gilead’s experimental drug remdesivir shows
‘hopeful’ signs in small group of coronavirus

patients

Two-thirds of severely ill patients showed improvement in
their oxygen therapy level when treated with the antiviral
drug
